BACKGROUND: @entity9 ( @entity9 ) is a @entity102 suffered by @entity1 with @entity15 ( @entity15 ), for which there is no cure. Underlying cellular mechanisms involved in its pathogenesis are multifaceted, presenting significant challenges in its management. METHODS: A randomized, double-blind, placebo-controlled study involving 15 relapsing-remitting @entity15 @entity1 with @entity15 -induced @entity9 was conducted to evaluate @entity36584 combined with @entity2682 (GBP). Eligible @entity1 stabilized on GBP (>= 1,800   mg/day) with inadequate @entity158 relief were recruited. @entity36584 or placebo was titrated over 4 weeks (0.5   mg/week increase) followed by 5-week maintenance of 1   mg oral @entity36584 (placebo) twice daily. Primary outcomes included two daily @entity1 -reported measures using a 100-mm visual analog scale (VAS), @entity158 intensity (VASpain ), and impact of @entity158 on daily activities (VASimpact ). @entity2357 modeling was conducted on each outcome to determine if within- @entity1 @entity158 trajectory differed across study groups, during 63-day follow-up. RESULTS: After adjustment for key @entity1 -level covariates (e.g., age, sex, Expanded Disability Status Scale, duration of @entity15 , baseline @entity158 ), a significant group       time(2) interaction term was reported for both the VASpain (P   <   0.01) and VASimpact score (P   <   0.01), demonstrating the adjusted rate of decrease for both outcomes was statistically greater in @entity36584 vs placebo study group. No significant difference in attrition rates was noted between treatments. @entity36584 was well tolerated, with @entity1296 /drowsiness most frequently reported. CONCLUSION: @entity36584 as an adjunctive to GBP is an effective, well-tolerated combination for @entity15 -induced @entity9 . The results of this study identify a novel therapeutic combination for use in this population of @entity1 predisposed to tolerability issues that may otherwise prevent effective @entity158 management.

XXXX as an Adjunctive to Gabapentin for @entity15 -Induced @entity9 : A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person'] @entity2682 :: ('MESH:C040029', 'Chemical') :: ['gabapentin'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic syndrome'] @entity2357 :: ('MESH:C537770', 'Disease') :: ['Hierarchical regression'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis'] @entity9 :: ('MESH:D009437', 'Disease') :: ['Neuropathic pain', 'NPP'] @entity36584 :: ('MESH:C011941', 'Chemical') :: ['nabilone', 'Nabilone']
@entity36584 :: (MESH:C011941,Chemical) :: ['Nabilone']
